Related Experiment Video
Updated: Jun 17, 2025

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
Blood Transcriptomic and Inflammatory Protein Biomarkers Associated with Imminent Pulmonary Exacerbation Risk in
Kang Dong1, Jiah Jang1, Casey P Shannon2
1Centre for Heart Lung Innovation, St. Paul's Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
None:
Rationale: The factors that lead to poor pulmonary exacerbation (PEx) outcomes in individuals with cystic fibrosis (CF) are still being investigated; however, delayed diagnosis and treatment are likely contributory. Identifying individuals at imminent risk of PEx could enable closer monitoring and/or earlier initiation of therapies to improve outcomes. Objectives: The goal of this study was to develop blood-based biomarkers that associate with imminent PEx risk in individuals with CF. Methods: We examined the whole-blood transcriptome and 55 inflammatory proteins from plasma and serum on 72 blood samples from 53 individuals with CF. Biomarker candidate genes and proteins were selected from 14 individuals with CF with paired stable and PEx visits (cohort 1). The biomarker candidates were then estimated and tested to classify individuals with CF who would experience a PEx within 4 months of a stable clinic visit or not (cohort 2). Results: A 16-gene panel and 9-protein panel were identified that could distinguish paired stable and PEx visits (area under the receiver operating characteristic curve [AUC] ± standard error = 0.83 ± 0.28 and 0.92 ± 0.18, respectively). These two panels also demonstrated strong performance in classifying individuals with CF who would experience a PEx within 4 months of a clinically stable visit or not (16-gene panel: AUC = 0.88; 9-protein panel: AUC = 0.83). In comparison, serum calprotectin and clinical variables (i.e., sex, precent predicted forced expiratory volume in 1 s, and the number of IV antibiotics in the preceding year) had AUCs of 0.75 and 0.71, respectively. Conclusions: Blood-based mRNA and protein biomarkers demonstrated strong performance in classifying individuals with CF at risk of imminent PEx. If the findings from this study can be validated, there is the potential to use blood biomarkers to enable more personalized disease activity monitoring in CF.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cystic Fibrosis: Management
Sinus disease and chronic...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

